Thursday, October 07, 2021
Avivagen Inc. (VIVXF)(VIV:CA)
Management Call on AB Vista Distribution Agreement
Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Agreement. As we had anticipated, Avivagen has entered into a distribution agreement focused on the U.S., Brazil, and Thailand markets. The 8-year agreement is with AB Vista. We expect the agreement to expand the adoption and use of OxC-beta in a number of high-value feed production markets worldwide. The AB Vista agreement should bring additional credibility for OxC-beta across the feed additive industry.
Who Is AB Vista? AB Vista is a a global animal nutrition technology company supplying feed additives, nutrition expertise and analytical services to animal feed and protein producers. The Company is one of the top distributors of feed enzymes worldwide, with a large technical sales force. We believe AB Vista will be able to leverage its existing relationships and distribution partnerships for …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
